Print

Orchid Chemicals & Pharmaceuticals Ltd.
Unaudited Financial Results for nine months ended December 31, 2006
(Rs.Lakhs)
   
Standalone Results
Consolidated Results
S.No
 Particulars
Three months ended
31-Dec-06
(Unaudited)
Three months ended
31-Dec-05
(Unaudited)
Nine months ended 31-Dec-06 (Unaudited)
 Nine months ended 31-Dec-05 (Unaudited) Year ended 31-Mar-06 (Audited)
Nine months ended 31-Dec-06 (Unaudited)
Nine months ended 31-Dec-05 (Unaudited)
Year ended 31-Mar-06 (Audited)
1
 Sales and Operating Income
23,873.33
23,760.49
68,617.44
64,717.80
88,876.64
72,127.92
69,562.37
95,193.99
2
 Other Income
26.36
49.86
126.56
205.03
132.73
151.69
207.08
121.90
3
 Total Expenditure
16,088.99
16,834.78
47,250.32
45,873.60
62,949.30
51,753.05
52,004.85
71,448.65
a) Decrease/(Increase) in Stock in trade
(3,461.05)
(534.78)
(12,862.76)
(4,008.31)
(1,912.72)
(12,924.33)
(4,585.74)
(2,048.83)
b) Consumption of raw materials
10,242.07
9,092.83
34,236.36
28,261.42
36,439.22
37,183.64
33,446.67
42,948.56
c) Staff Cost
1,924.01
1,796.65
5,734.23
4,755.06
6,521.18
5,859.64
4,858.01
6,963.89
d) Other Expenditure
7,383.96
6,480.08
20,142.49
16,865.43
21,901.62
21,634.10
18,285.91
23,585.03
4
Profit before Interest, Depreciation & Tax (1+2-3)
7,810.70
6,975.57
21,493.68
19,049.23
26,060.07
20,526.56
17,764.60
23,867.24
5
 Interest and Finance Charges
2,644.21
2,214.86
7,406.35
6,697.49
8,701.32
7,483.68
6,758.37
8,784.48
6
 Depreciation / Amortisation
2,038.14
1,865.32
5,979.82
5,690.18
8,297.57
6,181.48
5,878.37
8,581.76
7
 Profit before tax (4-5-6)
3,128.35
2,895.39
8,107.51
6,661.56
9,061.18
6,861.39
5,127.86
6,501.00
8
 Provision for Taxation
    Current Tax
-
(46.00)
-
-
-
-
-
-
    Deferred Tax
250.00
0.00
750.00
180.00
590.00
750.00
180.00
590.00
    Fringe Benefit Tax
46.00
45.00
121.00
130.00
181.00
121.00
130.00
181.00
9
 Net Profit (7-8)
2,832.35
2,896.39
7,236.51
6,351.56
8,290.18
5,990.39
4,817.86
5,730.00
10
 Paid- up Equity Share Capital (Face value of Rs. 10 each)
6,581.57
6,150.55
6,581.57
6,150.55
6,461.82
6,581.57
6,150.55
6,461.82
11
 Reserves excluding Revaluation Reserves
-
-
-
-
72,040.71
-
-
71,096.88
12
 Basic Earnings per Share (EPS) Rs.*
4.31
4.71
11.01
10.33
14.85
9.11
9.24
10.27
13
 Diluted Earnings per Share (EPS) Rs.*
3.85
4.32
9.84
9.46
13.64
8.15
8.95
9.43
14
 Aggregate of Non-Promoter Shareholding
  -Number of equity shares of Rs.10/-each
54,031,568
49,621,296
54,031,568
49,621,296
53,124,009
54,031,568
49,621,296
53,124,009
  -Percentage of Shareholding
82.10
80.68
82.10
80.68
82.21
82.10
80.68
82.21
   
* EPS is for the period not annualised.
  • The above financial results were taken on record by the Board of Directors at its meeting held on Friday, January 19, 2007.
  • The Company is operating in single segment (i.e) "Pharmaceuticals".
  • The above stand-alone results have been subjected to limited review by the Statutory Auditors.
  • The Allottment Committee of the Board have allotted shares to employees under ORCHID-ESOP 1999 Scheme as follows:
    - 4,000 shares at an adjusted price of Rs.200.44 per share on October 19, 2006
    - 550 shares at an adjusted price of Rs 168 per share on January 19, 2007.
  • During the quarter, the balance shares in Bexel Pharmaceuticals Inc. USA, were acquired by your company's wholly owned subsidiary.
  • The Company received 19 complaints during the quarter ended December 31, 2006 from the shareholders, all the complaints have been resolved and no complaints were pending as on December 31, 2006.
  • Previous period / year figures have been regrouped wherever necessary.

Place : Chennai
Date : January 19, 2007

For and on behalf of the Board

K.Raghavendra Rao
Managing Director